Evidence map›Paper›PMID 29294377›Full record

ArticleActa biomaterialia2018

Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly.

Huacheng He, Eleni Markoutsa, Jing Li, Peisheng Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biomaterialia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Acta pharmaceutica Sinica. B · 2021
    Article
  15. Review
  16. Disulfiram: a novel repurposed drug for cancer therapy.Cancer chemotherapy and pharmacology · 2021
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Huacheng HeDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter St., Columbia, SC 29208, United States.
Eleni MarkoutsaDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter St., Columbia, SC 29208, United States.
Jing LiDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter St., Columbia, SC 29208, United States.
Peisheng XuDepartment of Drug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, 715 Sumter St., Columbia, SC 29208, United States. Electronic address: xup@cop.sc.edu.

Funding

Brain targeted nanoparticle for Alzheimer's disease therapyR01AG054839 · NIA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI XU, PEISHENG · 2017 to 2021
$1.8M
Nano-cocktail overcomes multidrug-resistance for ovarian cancer therapyR15CA188847 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI XU, PEISHENG · 2015 to 2015
$366k
NCI NIH HHS R15 CA188847NIA NIH HHS R01 AG054839
6 · The paper itself

Abstract

Disulfiram (DSF), an FDA approved drug for the treatment of alcoholism, degrades to therapeutically active diethyldithiocarbamate (DDTC) in the body by reduction. Hereby, we developed a redox sensitive DDTC-polymer conjugate for targeted cancer therapy. It was found that the DDTC-polymer conjugate modified with a β-d-galactose receptor targeting ligand can self-assemble into LDNP nanoparticle and efficiently enter cancer cells by receptor-mediated endocytosis. Upon cellular uptake, the LDNP nanoparticle degrades and releases DDTC due to the cleavage of disulfide bonds, and subsequently forms copper (II) DDTC complex to kill a broad spectrum of cancer cells. 3D cell culture revealed that this nanoparticle shows much stronger tumor mass penetrating and destructive capacity. Furthermore, LDNP nanoparticles exhibited much greater potency in inhibiting tumor growth in a peritoneal metastatic ovarian tumor model. STATEMENT OF SIGNIFICANCE: The β-d-galactose receptor targeted disulfiram loaded nanoparticle (LDNP) is novel in the following aspects.

Indexed as

Drug RepositioningAcrylatesAnimalsBody WeightCell Line, TumorCell ProliferationDisulfiramKineticsMiceNanoparticlesNanotechnologyNeoplasmsParticle SizePolyethylene GlycolsProton Magnetic Resonance SpectroscopySpheroids, CellularAcrylatesacrylic acidDisulfiramPolyethylene GlycolsCancerDisulfiramNanoparticlePolymer-drug conjugateRepurpose

Identifiers

PMID29294377
PMCPMC5803356

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.